1. Scrip

Novo’s Low-Cost Wegovy Offers Alternative To Compounders For Self-Pay Crowd

Five Doses Available At $499 Per Month

 
• By Mandy Jackson

Novo is making Wegovy available through a new direct-to-patient delivery option for individuals paying out of pocket for the obesity drug as the potential end of semaglutide compounding nears.

Novo's lower-cost Wegovy options will be offered in pens while Lilly's cash-pay Zepbound products are in vials (Shutterstock)
Key Takeaways
  • Novo launched five doses of Wegovy for US cash-pay customers through NovoCare Pharmacy available at $499 per month as a lower-cost alternative for uninsured patients.

Novo Nordisk launched NovoCare Pharmacy on 5 March, through which it will sell monthly supplies of Wegovy (semaglutide) for $499...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 
• By Jessica Merrill

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

More from Business

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By Andy Smith

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.